Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,204,507 papers from all fields of science
Search
Sign In
Create Free Account
TRC102
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
methoxyamine
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A phase 1 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.
R. Meehan
,
G. Coyne
,
+17 authors
A. Chen
2016
Corpus ID: 79692398
2518Background: TRC102 inhibits BER by binding to abasic sites and acting as a topo II poison to cause DNA strand breaks; it…
Expand
2016
2016
A phase I study of daily oral TRC102 (methoxyamine) to enhance the therapeutic effects of pemetrexed in patients with advanced refractory cancer.
S. Anthony
,
L. Rosen
,
+6 authors
B. Leigh
Journal of Clinical Oncology
2016
Corpus ID: 22930801
2552 Background: TRC102 (methoxyamine) is a small molecule inhibitor of base-excision repair (BER) that enhances the cytotoxicity…
Expand
2015
2015
Abstract CT316: A phase I trial of oral TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with relapsed solid tumors
W. Jeong
,
K. Do
,
+14 authors
S. Kummar
2015
Corpus ID: 78650229
Background: Base excision repair (BER), one of the pathways of DNA damage repair, has been implicated in chemoresistance. TRC102…
Expand
2012
2012
Abstract 1743: Phase 1 clinical trial of the base-excision repair inhibitor Methoxyamine-HCl (TRC102; MX) in combination with Temozolomide (TMZ) in patients with solid tumors
P. Savvides
,
Yan Xu
,
+5 authors
S. Gerson
2012
Corpus ID: 72518446
Background: MX is the first base excision repair (BER) inhibitor evaluated in humans. MX blocks the BER pathway by covalently…
Expand
2012
2012
Abstract 753: Pharmacokinetic profile of the base-excision repair inhibitor methoxyamine-HCl (TRC102; MX) given as an one-hour intravenous infusion with temozolomide (TMZ) in the first in human phase…
P. Savvides
,
Yan Xu
,
+4 authors
S. Gerson
2012
Corpus ID: 72579466
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: MX is the first base excision repair…
Expand
2010
2010
Final results from a phase I study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in patients with refractory cancer.
G. Weiss
,
M. Gordon
,
+7 authors
B. Leigh
2010
Corpus ID: 76264581
2576 Background: TRC102 is a small-molecule inhibitor of base-excision repair (BER) that is nearly completely bioavailable after…
Expand
2010
2010
Abstract 682: Dual inhibition of BER by TRC102 and PARP inhibitor (ABT 888) synergistically enhances cytotoxicity of TMZ in human melanoma
A. Bulgar
,
Y. Miao
,
S. Gerson
,
Lili Liu
2010
Corpus ID: 84799319
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Melanoma, the most fatal skin cancer, has…
Expand
2010
2010
517 Combining pemetrexed with temozolomide and TRC102 (methoxyamine) causes synergistic cytotoxicity in melanoma cells
Lili Liu
,
A. Bulgar
,
B. Adams
,
C. Theuer
,
B. Leigh
,
S. Gerson
2010
Corpus ID: 72814828
2009
2009
A PHASE 1 STUDY OF ORAL TRC102 (METHOXYAMINE HYDROCHLORIDE), AN INHIBITOR OF BASE-EXCISION REPAIR, TO POTENTIATE THE THERAPEUTIC EFFECTS OF PEMETREXED IN PATIENTS WITH ADVANCED REFRACTORY CANCER
Gordon
,
G. Weiss
,
+10 authors
B. Leigh
2009
Corpus ID: 73966160
3 103.0 (93.6 - 239.0) 26.7 (25.4 - 28.0) 1654 (1332 - 4556) 100 mg/m 2 5 225.0 (74.9 - 385.0) 37.0 (25.3 - 45.5) 3697 (940…
Expand
2007
2007
Prevention of base excision repair by TRC102 (methoxyamine) potentiates the anti-tumor activity of pemetrexed in vitro and in vivo
Lili Liu
,
A. Bulgar
,
Jon R. Donze
,
B. Adams
,
C. Theuer
,
S. Gerson
2007
Corpus ID: 88656938
13005 Background: TRC102 (methoxyamine) reverses resistance to alkylating agents by inhibiting base excision repair (BER; a…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required